Predict your next investment

HEALTHCARE | Biotechnology
stratosgenomics.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$53.2M

About Stratos Genomics

Stratos Genomics is a biotechnology company that develops genome sequencing through the Sequencing by Expansion (SBX) method, a single-molecule detection process that circumvents the limitations of competing technologies.On June 1st, 2020 Stratos Genomics was acquired by Roche. The terms of the transaction were not disclosed.

Stratos Genomics Headquarter Location

World Trade Center East 2211 Elliott Ave. Suite #210

Seattle, Washington, 98121,

United States

206-448-7961

Latest Stratos Genomics News

Worldwide Long-Read Sequencing Industry To 2030 - Decreasing Cost Of Sequencing Is Driving Growth

Jul 16, 2021

Worldwide Long-Read Sequencing Industry To 2030 - Decreasing Cost Of Sequencing Is Driving Growth DUBLIN, July 16, 2021 /PRNewswire/ -- The "Global Long-Read Sequencing Market: Focus on Products and Services, Technology, Application, End User, Country Data (17 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2030" report has been... Author: Jul 16, 2021 6:30 AM EDT This premium market intelligence report highlights that the global long-read sequencing market is projected to reach $3,305.5 million by 2030. The study also highlights that the market is set to witness a CAGR of 21.15% during the forecast period 2021-2030. Long-read sequencing is one of the comprehensive methods for analyzing entire genomic analysis. Genomic information has been instrumental in identifying inherited disorders, characterizing the mutations that drive cancer progression, and tracking disease outbreaks. Further, long-read sequencing is the technique for sequencing all the genome and protein-coding genes in the genome. This technique includes the selection of the subset of the deoxyribonucleic acid (DNA) of the genome that encodes proteins or exons, which is followed by sequencing of the exome DNA using high throughput DNA sequencing methods. Long-read sequencing is also known as third-generation sequencing. Long-read sequencing is a DNA sequencing technique currently being researched to determine the nucleotide sequence of long sequences of DNA between 10,000 and 100,000 base pairs at a time. This technology removes the need to cut up of genome and then amplify DNA which is normally required in other DNA sequencing techniques. Market Segmentation Technology (Single-Molecule Real-Time (SMRT) Sequencing, Nanopore Sequencing, Synthetic Long-Read Sequencing, and Others) Application (Oncology, Infectious Diseases, Rare Diseases, Genetic Disorders, Metabolic Disorders, and Translational Research) End User (Academic and Research Institutions, Pharma and Biotech Companies, Clinical Laboratories, Hospitals and Clinics, and Other End Users) Regional Segmentation Increasing Number of Population Genomics Initiatives Market Challenges Challenges Pertaining to Genomic Data Centers Scarcity of Knowledge Dissemination Pertaining to Advanced Diagnostic Capabilities Market Opportunities Novel Diagnostic Applications Key Companies Profiled Agilent Technologies, Inc., Beijing Genomics Institute (BGI) Genomics Co., Ltd, Bionano Genomics, Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Longas Technologies Pty Ltd, Novogene Co., Ltd., Oxford Nanopore Technologies, Inc., Pacific Biosciences of California, Inc., PerkinElmer Inc., QIAGEN N.V., Quantapore, Inc., and Thermo Fisher Scientific Inc. Key Questions Answered in this Report: How is long-read sequencing revolutionizing the field of next generation sequencing? What are the major market drivers, challenges, and opportunities in the global long-read sequencing market? What are the underlying structures resulting in the emerging trends within the global long-read sequencing market? How is the COVID-19 pandemic impacting the global long-read sequencing market landscape? What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market? What are the key regulatory implications in developed and developing regions pertaining to long-read sequencing? What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region for the development of long-read sequencing? How is each segment of the market expected to grow during the forecast period 2021-2030, and what is the anticipated revenue to be generated by each segment? The segments are as follows: Products (systems, kits, and assays, software) and services Technology (single-molecule real-time (SRMT) sequencing, nanopore sequencing, synthetic long-read sequencing, and others) Application (oncology, infectious diseases, rare diseases, genetic disorders, metabolic disorders, and translational research) End user (academic and research institutions, pharma and biotech companies, clinical laboratories, hospitals and clinics, and other end users) Region ( North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World) What are the growth opportunities for the companies in the region of their operation? Who are the leading players with significant offerings in the global long-read sequencing market? Which companies are anticipated to be highly disruptive in the future, and why? What are the current unmet needs that are being faced in the global long-read sequencing market? Key Topics Covered: 1 Product Definition 2 Market Scope 3 Research Methodology 4 Market Overview4.1 Market Definition4.2 Market Footprint and Growth Potential4.3 COVID-19 Impact on Global Long-Read Sequencing Market 5 Market Dynamics5.1 Overview5.2 Impact Analysis5.3 Market Drivers5.3.1 Decreasing Cost of Sequencing5.3.2 Global Increase in Cancer Prevalence5.3.3 Increasing Number of Population Genomics Initiatives5.4 Market Restraints5.4.1 Lack of High Complexity Genomic Testing Centers in High Potential Markets5.4.2 Challenges Pertaining to Genomic Data Storage5.4.3 Scarcity of Knowledge Dissemination Pertaining to Advanced Diagnostic Capabilities5.5 Market Opportunities5.5.1 Massive Scope for Adoption of Genomic Data Analysis Software in Emerging Nations5.5.2 Novel Diagnostic Applications 6 Industry Insights6.1 Overview6.2 Legal Requirements and Framework in the U.S.6.2.1 FDA Regulation6.2.2 Centers for Medicare and Medicaid Services (CMS) Regulation6.3 Legal Requirements and Framework in Europe6.4 Legal Requirements and Framework in Asia-Pacific6.4.1 China6.4.2 Japan 7 Competitive Landscape7.1 Acquisitions7.2 Synergistic Activities7.3 Product Launches and Upgradations7.4 Market Share Analysis (by Company), 2019 and 20207.5 Growth Share Analysis7.5.1 Growth Share Analysis (by Technology)7.5.2 Growth Share Analysis (by Application) 8 Global Long-Read Sequencing Market (by Products and Services), $Million, 2020-20308.1 Overview8.2 Products8.2.1 Systems8.2.2 Kits and Assays8.2.3 Software8.3 Services 9 Global Long-Read Sequencing Market (by Technology), $Million, 2020-20309.1 Overview9.2 Single-Molecule Real-Time (SMRT) Sequencing9.3 Nanopore Sequencing9.4 Synthetic Long-Read Sequencing9.5 Other Sequencing Technologies 10 Global Long-Read Sequencing Market (by Application), $Million, 2020-203010.1 Overview10.2 Oncology10.3 Infectious Diseases10.4 Rare Diseases10.5 Genetic Disorders10.6 Metabolic Disorders10.7 Translational Research 11 Global Long-Read Sequencing Market (by End User), $Million, 2020-203011.1 Overview11.2 Academic and Research Institutions11.3 Pharma and Biotech Companies11.4 Clinical Laboratories11.5 Hospitals and Clinics11.6 Other End Users 12 Global Long-Read Sequencing Market (by Region), $Million, 2020-203012.1 Overview12.2 North America12.2.1 U.S.12.2.2 Canada12.3 Europe12.3.1 Germany12.3.2 U.K.12.3.3 France12.3.4 Italy12.3.5 Spain12.3.6 Netherlands12.3.7 Russia12.3.8 Rest-of- Europe12.4 Asia-Pacific12.4.1 China12.4.2 Japan12.4.3 India12.4.4 South Korea12.4.5 Australia12.4.6 Singapore12.4.7 Rest-of- Asia-Pacific12.5 Latin America12.5.1 Brazil12.5.2 Mexico12.5.3 Rest-of- Latin-America12.6 Rest-of-the-World (RoW) 13 Company Profiles13.1 Overview13.2 Agilent Technologies, Inc.13.2.1 Company Overview13.2.2 Role of Agilent Technologies, Inc. in the Global Long-Read Sequencing Market13.2.3 Financials13.2.4 Key Insights About Financial of the Company13.2.5 SWOT Analysis13.3 Beijing Genomics Institute (BGI) Genomics Co., Ltd13.3.1 Company Overview13.3.2 Role of Beijing Genomics Institute (BGI) Genomics Co., Ltd in the Global Long-Read Sequencing Market13.3.3 SWOT Analysis13.4 Bionano Genomics, Inc.13.4.1 Company Overview13.4.2 Role of Bionano Genomics, Inc. in the Global Long-Read Sequencing Market13.4.3 Financials13.4.4 Key Insights About Financial Health of the Company13.4.5 SWOT Analysis13.5 F. Hoffmann-La Roche Ltd13.5.1 Company Overview13.5.2 Role of F. Hoffmann-La Roche Ltd in the Global Long-Read Sequencing Market13.5.3 Financials13.5.4 Key Insights About Financial Health of the Company13.5.5 SWOT Analysis13.6 Illumina, Inc.13.6.1 Company Overview13.6.2 Role of Illumina, Inc. in the Global Long-Read Sequencing Market13.6.3 Financials13.6.4 Key Insights About Financial Health of the Company13.6.5 SWOT Analysis13.7 Longas Technologies Pty Ltd13.7.1 Company Overview13.7.2 Role of Longas Technologies Pty Ltd in the Global Long-Read Sequencing Market13.7.3 SWOT Analysis13.8 Novogene Co., Ltd.13.8.1 Company Overview13.8.2 Role of Novogene Co., Ltd. in the Global Long-Read Sequencing Market13.8.3 SWOT Analysis13.9 Oxford Nanopore Technologies, Inc.13.9.1 Company Overview13.9.2 Role of Oxford Nanopore Technologies, Inc. in the Global Long-Read Sequencing Market13.9.3 SWOT Analysis13.1 Pacific Biosciences of California, Inc.13.10.1 Company Overview13.10.2 Role of Pacific Biosciences of California, Inc. in the Global Long-Read Sequencing Market13.10.3 Financials13.10.4 Key Insights About Financial Health of the Company13.10.5 SWOT Analysis13.11 PerkinElmer, Inc.13.11.1 Company Overview13.11.2 Role of PerkinElmer Inc. in the Global Long-Read Sequencing Market13.11.3 Financials13.11.4 SWOT Analysis13.12 QIAGEN N.V.13.12.1 Company Overview13.12.2 Role of QIAGEN N.V. in the Global Long-Read Sequencing Market13.12.3 Financials13.12.4 Key Insights About Financial Health of the Company13.12.5 SWOT Analysis13.13 Quantapore, Inc.13.13.1 Company Overview13.13.2 Role of the Quantapore, Inc. in the Global Long-Read Sequencing Market13.13.3 SWOT Analysis13.14 Thermo Fisher Scientific Inc.13.14.1 Company Overview13.14.2 Role of Thermo Fisher Scientific Inc. in the Global Long-Read Sequencing Market13.14.3 Financials13.14.4 Key Insights About Financial Health of the Company13.14.5 SWOT Analysis13.15 Snapshot13.15.1 Stratos Genomics13.15.1.1 Company Overview13.15.1.2 Role of Stratos Genomics in the Global Long-Read Sequencing Market For more information about this report visit https://www.researchandmarkets.com/r/r6v0ce Media Contact: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 View original content: https://www.prnewswire.com/news-releases/worldwide-long-read-sequencing-industry-to-2030---decreasing-cost-of-sequencing-is-driving-growth-301335506.html

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Stratos Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Stratos Genomics is included in 2 Expert Collections, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Stratos Genomics Patents

Stratos Genomics has filed 30 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • DNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/12/2017

5/4/2021

Molecular biology, Biotechnology, DNA sequencing, DNA, Genetics

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/12/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

5/4/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, Biotechnology, DNA sequencing, DNA, Genetics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Stratos Genomics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Stratos Genomics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.